Related Experiment Video
Updated: Mar 21, 2026
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
16.6K
Botulinum toxin type B for cervical dystonia.
Raquel E Marques1, Gonçalo S Duarte, Filipe B Rodrigues
1Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, Lisboa, Portugal, 1649-028.
The Cochrane Database of Systematic Reviews
|May 14, 2016
Summary
Botulinum toxin type B (BtB) effectively reduces cervical dystonia symptoms and pain compared to placebo. However, it increases the risk of dry mouth and swallowing difficulties, with limited data on long-term use.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cervical dystonia is a disabling condition causing painful head posturing.
- Botulinum toxin type A (BtA) is a common first-line treatment, with botulinum toxin type B (BtB) as an alternative.
Purpose of the Study:
- To evaluate the efficacy, safety, and tolerability of botulinum toxin type B (BtB) compared to placebo for cervical dystonia.
Main Methods:
- A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) of BtB in adults with cervical dystonia.
- Searched databases including CENTRAL, MEDLINE, and EMBASE from 1977 to 2015.
- Assessed primary outcomes of symptom improvement and adverse events.
Main Results:
- Four RCTs (441 participants) showed BtB significantly improved cervical dystonia symptoms, reducing severity and pain scores compared to placebo.
- Patients and clinicians reported subjective improvements, but BtB treatment increased risks of dry mouth and dysphagia.
- Higher BtB doses correlated with longer duration of effect and increased adverse events, though all tested doses were efficacious.
Conclusions:
- A single BtB treatment session offers significant clinical benefits for cervical dystonia but carries risks of dry mouth and dysphagia.
- Further RCTs are needed to assess repeated BtB cycles, optimal dosing, injection techniques, and quality of life impact.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
01:28Classification of Skeletal Muscle Relaxants
3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
01:19Depolarizing Blockers: Pharmocokinetics
706
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
706
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.2K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.2K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.4K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.4K